ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0100

COVID Vaccinations in Patients with Rheumatologic Diseases- perspectives and Disparities in a Safety-net Tertiary Care Hospital in Memphis, Tennessee
Abstract Number: 0188

COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
Abstract Number: 1776

COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
Abstract Number: 1766

COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Abstract Number: 0219

COVID-19 Impact on Second Year Medical Students Experience with Interactive Patient Encounters as a Supplement to Teaching the Skin and Rheumatology Course
Abstract Number: 0440

COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
Abstract Number: 2081

COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Abstract Number: 1961

COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
Abstract Number: 0895

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
Abstract Number: 2084

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
Abstract Number: 0177

COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Abstract Number: 0083

COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
Abstract Number: 1328

CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
Abstract Number: 2147

Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
Abstract Number: 1971

Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].